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A major objective in biological research is to understand
spatial and temporal requirements for any given gene, especially
in dynamic processes acting over short periods, such as
catalytically driven reactions, subcellular transport, cell division,
cell rearrangement and cell migration. The interrogation of such
processes requires the use of rapid and flexible methods of
interfering with gene function. However, many of the most
widely used interventional approaches, such as RNAi or CRISPR
(clustered regularly interspaced short palindromic repeats)-Cas9
(CRISPR-associated 9), operate at the level of the gene or
its transcripts, meaning that the effects of gene perturbation
are exhibited over longer time frames than the process under
investigation. There has been much activity over the last few
years to address this fundamental problem. In the present
review, we describe recent advances in disruption technologies
acting at the level of the expressed protein, involving inducible
methods of protein cleavage, (in)activation, protein sequestration
or degradation. Drawing on examples from model organisms we
illustrate the utility of fast-acting techniques and discuss how
different components of the molecular toolkit can be employed to
dissect previously intractable biochemical processes and cellular
behaviours.
Key words: biochemical techniques and resources, cellular
targeting, chemical biology, protein dynamics, optogenetics.
INTRODUCTION
Genetic manipulation, which operates at the level of the gene
or its transcribed product, has proven to be indispensable
for the identification of molecular components required for
biological processes and understanding how these components
act together to construct functional cells, tissues and organisms.
There are now a myriad of tools for mutational analysis
that have been accumulated for over a century, fuelling gene
discovery through forward genetic screens and facilitating reverse
genetics to probe gene function [1–3]. Recent developments,
in particular CRISPR (clustered regularly interspaced short
palindromic repeats)-based approaches and RNAi, promise
to further transform our understanding by facilitating high-
throughput reverse genetics and gene editing with nucleotide-
level precision [4,5]. Gene overexpression technologies have
also become extremely advanced, featuring a high level of
spatial and temporal control that has enabled a range of
developmentally targeted gain-of-function studies. Heterologous
gene expression systems, such as yeast Gal4/UAS (GAL4
upstream activating sequence), have proven to be particularly
versatile in this regard [6]. Yet, quite often, the genetic tools
used to perturb gene function are not able to keep pace with
dynamic biological events that can act over different timescales
from less than a second to many hours or days, depending on the
process.
Processes acting over short times are particularly recalcitrant
to genetic analysis because there is a considerable delay
between perturbations at the transcriptional or post-transcriptional
level and the corresponding effect on the encoded protein.
Consequently, genetic approaches are typically incapable of
selectively disrupting the encoded protein of interest at the time
when the effects of experimental manipulation are measured.
This is particularly a problem for analysing the function of
proteins required at multiple points of the same process. A partial
solution to this problem might be to monitor the process under
investigation in real-time, so as to capture more information
about the biological effects than can be revealed at a fixed time
point [7]. Yet significant limitations remain, especially for the
analysis of protein function in vivo. For instance, mutation of
a gene required for development might result in early lethality
making later processes impossible to analyse. Alternatively in
the case of transgenic RNAi, which typically results in partial
loss-of-function, it may not be possible to drive expression of
the transgene early enough for knockdown to occur before the
process has already taken place. This is particularly a problem
early in development, where it can take a considerable time for
the maternal contribution of RNA and protein to be exhausted.
Another major consideration is the existence of compensatory
homoeostatic mechanisms that may circumvent the requirement
for the protein under investigation. Although this is often a reason
cited for lack of knockout phenotypes in mice, the underlying
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mechanisms are frequently not well described. Studies employing
fast-acting methods have the potential to resolve such issues,
as illustrated by a study of the cell-surface glycoprotein CD44
[8]. CD44 isoforms act as co-receptors for the receptor tyrosine
kinases c-Met and VEGFR-2 (vascular endothelial growth factor
receptor 2), but do not produce overt phenotypes when knocked
out in mice [8]. Using blocking antibodies, it was shown that
acute disruption of CD44v6 inhibited cell proliferation and c-
Met activation in wild-type mice, but that ICAM-1 (intercellular
adhesion molecule 1) compensated for the CD44v6 isoform in
CD44-null mice [8]. This study illustrates that rapid blockade of
protein function can be a powerful way of resolving problems
associated with slow-acting or constitutive methods of gene
disruption. However, only a minority of proteins are currently
open to pharmacological manipulation and the development of
specific blocking reagents for every protein of interest based on
their intrinsic properties is a long way away.
A successful strategy that has been adopted by the research
community over the last few years to increase the range of targets
that can be manipulated pharmacologically has been to take
well-characterized ligand-interaction domains from heterologous
systems, and genetically engineer them into proteins of interest.
In parallel to this chemical genetics approach, researchers have
also found ways of incorporating domains responsive to other
triggers, such as light, temperature and pH. This has spawned
a new generation of tools that act directly at the level of the
expressed protein and have the potential to provide insight into
acute perturbations, give access to analysis over short times and
allow reversible switching. Such tools can be broadly categorized
according to their mode of action: those that disrupt protein
activity through complex (de)formation, (in)activate proteins by
induced splicing or cleavage, or directly target a protein for
degradation through the endogenous cell machinery. In the present
review, we focus primarily on tools for conditional control of
protein function that fall into one of these three categories and are
fast acting, providing examples of their application as a guide to
researchers considering their use.
COMPLEX FORMATION
The promotion of interactions between proteins of interest
represents a powerful strategy for the conditional control of
protein activity. There are a number of different mechanisms by
which such interactions can be engineered to spatiotemporally
regulate protein activity in response to different stimuli, in a way
that is both precise and fast acting (Figure 1, Table 1).
Chemically induced dimerization
One of the first mechanisms involving engineered protein complex
formation utilized small molecules, referred to as chemical
inducers of dimerization (CIDs), which simultaneously bind
domains engineered into two proteins of interest, bringing them
into close proximity and promoting their interaction (Figure 1A,
Table 1). Methods involving CIDs can influence protein activity by
promoting (dis)aggregation, altering transcription or by changing
the sub cellular localization of target proteins. The application of
CIDs to control protein activity and study protein function spans
the last two decades, with the majority of applications utilizing
naturally occurring CIDs, found to dimerize specific protein–
ligand pairs [9–11]. For a small molecule to be successful in CID
approaches it must have the ability to simultaneously bind two
proteins, and therefore must have two high-affinity highly specific
protein-binding domains, joined in a way that allows both target
proteins to bind and interact [12].
FK1012
The first, naturally occurring CID, FK1012, was reported in
1993 [14]. FK1012 is a derivative of the immunosuppressant
drug FK506, which was found in 1991 to be capable of binding
calcineurin and FK506-binding protein [12] (FKBP12) with
high affinity [13]. FK1012 is a synthetic dimer of FK506 that
lacks the intrinsic biological activity of FK506 and has since
been utilized as a CID to bind multiple FKBP12 domains [14],
bringing target proteins together in a defined reversible fashion
and demonstrating the subtleties required for successful CID
design [12]. The initial CID concept was demonstrated through
a system in which addition of FK1012 activated the endogenous
T-cell signalling cascade, via fusion of FKBP12 to the proximity-
regulated ζ -chain of the T-cell receptor, leading to receptor
aggregation and subsequent activation [14]. FK1012 and other
CIDs capable of dimerizing a single protein domain, discovered in
the years following, have since been applied to the study of many
important cellular processes to, for example, induce apoptosis
via aggregation of the Fas membrane signalling protein [15] or
regulate transcription through ligand-dependent (dis)association
of transcriptional activators with promoter regions [16].
Rapamycin
Although the first CIDs were only capable of homodimerization,
these approaches could, in theory, be used to generate
heterodimers if two proteins of interest were tagged with the
same domain. The result would, however, be a mixture of
heterodimers and homodimers of the two individual proteins
of interest. The development of methods involving naturally
occurring heterodimerizers therefore followed, with the most
notable heterodimerizer rapamycin dominating the field since
its discovery [17]. Rapamycin is an immunosuppressant drug
that selectively binds both FKBP12 and FKBP–rapamycin)
associated protein (FRAP)/mammalian target of rapamycin
(mTOR) [18]. The FKBP and FKBP–rapamycin-binding (FRB)
domains of these proteins, respectively, are sufficient for binding
and retain the binding affinity of the full-length proteins [19].
A key step in the application of rapamycin as a CID was
the production of rapamycin derivatives, known as ‘rapalogs’,
which have a much lower affinity for endogenous proteins,
thereby circumventing rapamycin’s immunosuppressive activity.
In parallel, the rapamycin-binding regions from FKBP12 and
FRAP/mTOR were remodelled to bind the rapalog at nanomolar
affinity, providing an orthologous rapamycin system for CID
applications [20–22]. These rapalogs have since been used to
conditionally dimerize proteins to interrogate many different
biological processes. Notable examples include the study of
mitosis, in which rapamycin-induced binding of the endoplasmic
reticulum and Golgi membranes showed that these structures
remain segregated during mitosis in mammalian cells [23], and
also the study of phosphoinositides and their roles in endocytosis
and intracellular trafficking [24,25].
One specific application of rapamycin-mediated control in
mammalian cells is the knocksideways (KS) method (Table 1),
which acutely sequesters protein activity through a change
in subcellular localization. The KS method is capable of
rapidly re-routing target proteins containing an FKBP domain
to the mitochondria on a timescale of seconds, through
rapamycin-induced binding to an FRB-containing protein with
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Figure 1 Schematic representation of methods for the control of protein activity by induced complex formation
Methods described here can be broadly categorized by their method of induction. (A) Generalized mechanism for small-molecule-mediated approaches involving small-molecule CIDs to sequester
protein activity by promoting (dis)aggregation, altering transcription or by changing the subcellular localization of target proteins. (B) A specific example of this approach is illustrated by the
knocksideways (KS) method, which involves the rapid sequestration of target proteins to the mitochondria through rapamycin-mediated interaction between the FKBP-tagged target protein and
the mitochondrially localized mito-RFP-FRB trap. (C) The generalized mechanism for light-based approaches induced by exposure to a specific wavelength of light. More specific examples of
light-based methods are also illustrated in (D) and (E). (D) Schematic depiction of the LARIAT method, whereby target proteins tagged with CRY2 are sequestered into large protein complexes upon
a light-induced conformational change to produce the photoactivated form of CRY2. This interacts with CIB1-bound multimeric complexes to aggregate the target protein and sequester activity. (E)
Representation of LOV-domain-based approaches, which involve a light-induced conformational change leading to unravelling of the Jα helix and the loss of its interaction with the LOV domain
leaving the target protein free to bind interactors and perform its function.
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
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Table 1 Summary of methods for conditional control of protein complex formation
Can be induced by
Technique Protein disruption Timescale Small molecule/hormone Light Temperature pH
Chemically induced dimerization (CID) Sequestration/(in)activation min/h
√
e.g. FK1012, rapamycin   
Knocksideways (KS) Sequestration min
√
Rapamycin   
Light-activated dimerization Sequestration/(In)activation s/min 
√
 
Light-activated reversible inhibition by assembled trap (LARIAT) (In)activation s 
√
Blue light: 450–495 nm  
Light-oxygen-voltage (LOV) domains (In)activation s/min 
√
Blue light: 450–495 nm  
a mitochondrial targeting signal (mito-FFP-FRB) (Figure 1B)
[26]. This method utilizes the principle of mitochondrial re-
routing, whereby the protein of interest accumulates on the
outer mitochondrial membrane in a way that, providing the new
localization is not compatible with protein function, sequesters
protein activity, but remains tolerable to cells [27]. In an initial
proof-of-principle study, the KS method was used to study the
role of two subunits of the adaptor protein (AP) complexes of
clathrin-coated vesicles AP-1 and AP-2 [26]. Robinson et al.
[26] used rapamycin-induced re-routing of AP-1 and AP-2 to
the mitochondria, in combination with siRNA knockdown of
the endogenous protein, to demonstrate the requirement for both
proteins in the endocytosis pathway. Although the phenotype of
AP-2 sequestration was similar to that resulting from siRNA
approaches alone, the corresponding phenotype observed for
AP-1 was distinct from that of the siRNA knockdown and is
accredited to more rapid depletion achieved in the KS approach
[26]. The effectiveness of the KS approach for rapid changes
in protein activity has since been demonstrated in a number
of varied applications to fast-acting processes in mammalian
cells. For example, Cheeseman et al. [28] used the rapamycin-
mediated approach to specifically remove TACC3-ch-TOG-
clathrin complexes from the mitotic spindle within a timescale
of 5 min following rapamycin addition. By re-routing these
complexes to the mitochondria and away from mitotic spindles
at defined stages in mitosis they were able to deduce their role in
maintaining tension in kinetochore fibres, which are essential for
correct segregation of chromosomes. Again, this phenotype was
distinct from that observed with siRNA alone, demonstrating the
utility of the KS approach.
CIDs offer an efficient way to control the dynamics of processes
reliant on oligomerization. However, the same principles can also
be used for the opposite mode of control, in which processes
are inhibited by oligomerization and activated upon addition
of a ligand that dissociates the complexes. To enable this
mode of control, Rollins and colleagues identified an FKBP12
mutant F36M-FKBP (FM) with the ability to form discrete
dimers that can be dissociated rapidly upon addition of ligand
[22]. Using these tools, Al-Bassam et al. [29] were able to
develop a novel pulse–chase system in which exogenous FM-
tagged membrane proteins were accumulated gradually in the
endoplasmic reticulum, and sequestered by the formation of
aggregates. Within minutes of small-molecule ligand addition, the
FM domains dissociated and the accumulated membrane proteins
could be simultaneously released for synchronous continuation
along the secretory pathway [29]. Through this method, Al-
Bassam et al. [29] were able to study proteins in a specific phase
of the secretory pathway without interference from proteins in
other phases of the pathway and thus overcome a major problem
associated with studying this dynamic process.
In order for CID to be successful, target proteins must be
considered on a case-by-case basis and prior knowledge of
protein function is usually required in order to achieve thorough
inactivation. With nanomolar affinities between ligand–protein
pairs, CID approaches have high specificity and high efficiency.
However, this puts them at a disadvantage in terms of reversibility,
as they often require an additional ligand that competes for
binding to relieve protein inactivation/sequestration. Effects are
often irreversible [30]. Although CID approaches were initially
developed and demonstrated in vitro, these applications have
since been developed to allow in vivo studies [31]. However, the
requirement for exogenous small ligand addition and resulting
potential for off-target effects somewhat limit the practicality of
such applications. Also, although the KS approach demonstrates
the ability for CID approaches to operate on a timescale of
minutes, generally CID based methods range from minutes to
hours, limited by the requirement for efficient uptake of the
chemical inducer, and are consequently not among the fastest
acting tools for temporal control of protein dynamics.
Light-induced dimerization (LID)
Another way in which protein dimerization can be induced is via
light-based methods, which take advantage of naturally occurring
photosensitive protein domains that dimerize upon exposure to
a certain wavelength of light (Figure 1C, Table 1). Although
maintaining the flexibility of CID approaches in terms of the
response elicited and the many ways in which protein function
can be disrupted, light-based methods generally overcome many
of the limitations of CID. In particular, they provide improved
spatiotemporal precision, mitigate the requirement for exogenous
small molecule addition and operate on a timescale of seconds.
Genetically encoded light-based (optogenetic) approaches have
vastly expanded within the last decade from just a few applications
to a whole toolbox of techniques with which to control protein
activity [32]. Like CID, the first methods involving light-
induced dimerization (LID) took advantage of naturally occurring
photosensitive proteins, often discovered initially in plants, known
as phytochromes and cryptochromes.
Phytochromes
Phytochromes are photoreceptive pigments encoded by small
multigene families in plants and bacteria where they monitor
red/far-red wavelengths of light [33,34]. The most thoroughly
investigated phytochromes are those from Arabidopsis thaliana,
which normally function to modulate seed germination and shade
avoidance [35]. One such protein is phytochrome B (PhyB) which
undergoes a conformational change upon exposure to light of
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visible red wavelengths (∼650–670 nm) to heterodimerize with
the transcription factor phytochrome-interacting factor 3 (PIF3).
Unlike other photosensitive proteins, this dimerization can be
reverted through exposure to longer wavelengths of light (∼700–
750 nm), which induces monoisomerization of PhyB and releases
PIF3, allowing for very precise control of protein activity [32,36].
Cryptochromes
Also commonly found in plants, cryptochromes (Cry) are
plant photosensors that absorb blue light, the most well
studied of which, Cry2, heterodimerizes with the cryptochrome-
interacting basic helix–loop–helix 1 (CIB1) transcription factor.
Cryptochrome proteins have a C-terminal domain required for
signal transduction and, like phytochromes, require a flavin
adenine dinucleotide (FAD) chromophore cofactor, which binds to
an N-terminal DNA photolyase homology region (PHR) [37,38].
Since the discovery of Cyr2 and its ability to heterodimerize
with CIB1, this system has been adapted to circumvent the need
for exogenous chromophore addition [37]. With this improved
system, Kennedy et al. [37] induced dimerization of Cry2–
CIB1 on a sub-millisecond timescale (in under 300 μs), although
the reverse process took minutes to complete. Nevertheless,
this improved system has since been used in the study of
a number of different cellular processes in model organisms.
One field in which the Cry2–CIB1 system has been used
successfully both in vitro [39] and in vivo [40] is the study of
phosphoinositide signalling. This was achieved by Cry2–CIB1-
mediated recruitment of a phosphoinositide phosphatase catalytic
subunit responsible for the conversion of PI(4,5)P2 into PI(4)P
to the plasma membrane in a light-dependent manner. Using
this approach, Guglielmi et al. [40] were able to study complex
morphological changes and interactions that occur within defined
timescales during Drosophila embryogenesis. The recruitment
of the catalytic subunit to the plasma membrane within seconds
of blue light illumination was sufficient for quick depletion of
PI(4,5)P2 which, given the role of phosphoinositides in regulating
actin polymerization, allowed control over cell contractility and
facilitated the study of cell–cell interactions, force transmission
and changes in tissue geometry [40].
The use of cryptochromes for conditional dimerization has
since spawned a host of methods utilizing the interaction between
Cry2 and binding partners such as CIB1. One such method,
known as light-activated reversible inhibition by assembled
trap (LARIAT), utilizes light-mediated heterodimerization to
reversibly sequester target proteins into multimeric complexes
in mammalian cells, by engineered interactions with multimeric
proteins (Figure 1D, Table 1) [41]. Lee et al. [41] developed
the LARIAT technique by fusing Ca2 + /calmodulin-dependent
protein kinase IIα (CaMKIIα) protein, which self-assembles
into a 12-subunit oligomer, to CIB1. Upon blue light
stimulation, CIB1 interacts with Cry2 and forms clusters through
interconnections between CIB1-conjugated CaMKIIα multimeric
proteins. Through this method of optogenetic trapping, Lee
et al. [41] were able to induce cluster formation with high
spatiotemporal precision in HeLa cells within 30 s of illumination,
with cluster disassembly occurring within minutes of light
withdrawal. Lee et al. [41] also found that the extent of clustering
was correlated with the intensity or number of light pulses
administered, suggesting that it may be possible to quantitatively
control clustering simply by varying light conditions for more
intricate control of protein dynamics. This approach can also
be used to inactivate GFP-tagged proteins, without the need
to add an additional protein tag, through the use of anti-
GFP nanobodies. To demonstrate this approach, Lee et al. [41]
trapped a number of different GFP-tagged proteins into complexes
through interactions with a CIB1-conjugated anti-GFP nanobody
to acutely disrupt proteins involved in fast-acting processes such
as membrane retention and spindle formation.
A recent example that displays the potential of the LARIAT
approach is its application to the study of intracellular membrane
trafficking. Here, Nguyen et al. [42] developed a system whereby
intracellular membranes can be rapidly and reversibly sequestered
into complexes via Cry2-induced aggregation of CIB1-conjugated
GTPases. Using diverse Rab GTPases as membrane markers,
it was possible to access specific intracellular membrane
compartments such as the Golgi and endoplasmic reticulum [42].
This approach makes it possible to dissect the spatiotemporal
functions of intracellular membranes in a variety of processes such
as receptor transport, intracellular signalling from endosomes,
protein sorting and secretion.
It is also known that many plant photosensors, including
Cry2, are capable of forming aggregates upon light stimulation
[43,44]. For example, Wend et al. [45] demonstrated the ability
of Cry2 to dimerize C-Raf and activate its kinase activity in
a light-inducible manner, functionally separating C-Raf from
upstream growth factor signalling, enabling a more controlled
approach to study dynamic downstream effects on target protein
phosphorylation and cell signalling. Interestingly Wend et al.
[45] also tested the ability of C-Raf-Cry2 to dimerize with
CIB1-bound C-Raf and found a weaker activation of C-Raf,
which they suggest may be due to a difference in stoichiometry
when the larger Cry2 molecule binds to the much smaller CIB1
domain. Another use of Cry2 dimerization is in a technique
called clustering indirectly using cryptochrome 2 (CLICR), which
involves the clustering of transmembrane receptors to activate
signal transduction (Figure 2). This is achieved by indirect
clustering of Cry2 bound to a receptor-binding domain (BD); high
local concentrations of the BD then serve to cluster endogenous
receptors leading to signal activation [46]. An N-terminal src-
homology 2 (SH2) domain, which binds receptor tyrosine kinases
(RTKs) and the phosphotyrosine-binding-like F3 domain from
talin, which binds β3-integrin were shown to be effective BDs
[46], suggesting the method could be modified to target a wide
range of transmembrane proteins. However, the selectivity of such
tools needs to be empirically validated for each system.
Light–oxygen–voltage domains
An alternative approach to light-induced dimerization involves
the use of light–oxygen–voltage (LOV) domains from Avena
sativa phototropin 1 (Table 1). LOV domains contain a C-terminal
α-helix (Jα helix) which, upon light illumination and excitation
of a flavin cofactor within the LOV domain, undergoes a large
conformational change and unwinds [47]. This light-induced
structural change allows for the control of protein activity through
allosteric regulation of proteins containing these LOV domains
(Figure 1E). One example of how LOV domains have aided the
study of protein function is the application to the study of cell
motility [48,49]. Wu et al. [48] fused Rac1 to a LOV domain,
which, in its native α-helix state, blocked Rac1 interactions. This
photo activatable Rac1 (PA-Rac1) could then be reversibly and
repeatedly activated in precise cellular locations by illumination
with blue light, producing localized cell ruffling and protrusions.
Localized Rac1 activation was also able to promote directed
cell motility [48]. PA-Rac analogues have since been used in
further in vivo cell migration studies, showing for instance that
Rac activation is sufficient for polarization of the border cells in
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Figure 2 Clustering indirectly using cryptochrome 2 (CLICR)
In the dark un, induced state, monomers of Cry2 fused to a receptor targeting BD (Cry2–BD) exist in an unclustered state and therefore have a weak affinity for the target receptor. Upon blue light
stimulation, Cry2–BD molecules oligomerize, increasing the local concentration of BD and conferring a high avidity for the target receptor. These oligomers undergo membrane translocation and
cluster target transmembrane receptors.
Drosophila oogenesis and that the directionality of the subsequent
migration of these cells during egg chamber development is
dependent on Rac levels [50]. Although PA-Rac has been used
successfully in a number of studies, the shift between the wound
and unwound Jα helix states upon illumination is less than ideal,
with at best a 10-fold shift towards the unfolded state upon
light irradiation [51]. Through the identification of mutations that
stabilize both the wound and unwound Jα helix states, Strickland
et al. [52] modified the LOV system and reduced the proportion
of unwound Jα helix in the dark state to make the switch between
light and dark states more defined and increase the dynamic range
of the system as a whole, with up to a 70-fold shift in Jα helix
state after exposure to light.
One example that takes advantage of the high spatial and
temporal precision that can be achieved using LOV domains is
the control of RTK activation. RTKs are a family of cell-surface
receptors that respond to growth factor and hormone signals to
regulate a variety of cell behaviours, and have previously proven
difficult to study due to the rapid rates of receptor biosynthesis and
degradation that can occur. Grusch and colleagues [54] used LOV-
domain-mediated dimerization of mutant RTKs, insensitive to
endogenous ligands, to induce transphosphorylation and therefore
receptor activation on a timescale shorter than that of receptor
synthesis/degradation. Through this approach they were able to
mimic the cell behaviours induced by endogenous growth factors
to provide control over cell signalling on the minute timescale,
with diverse cellular responses in different cell types pointing
to the involvement of different adapter proteins or feedback
mechanisms [54].
Light-based methods for induced protein complex formation
and control of protein activity offer a powerful solution to many of
the drawbacks that come with chemical-based approaches while
maintaining versatility. Although light-based methods require
laser excitation to stimulate photoactivatable protein modules,
the wavelengths of light used generally fall within the same range
as those used for conventional fluorescence imaging, meaning
cytotoxic effects are minimal and these approaches have therefore
been applied successfully to both in vivo and in vitro studies [55].
The benefits of optogenetic approaches over the more traditional
well-studied small-molecule approaches suggest that, with further
development, these tools will be invaluable in the use of complex
formation for protein inactivation or sequestration in the study of
fast-acting cellular processes.
PROTEIN CLEAVAGE/SPLICING
Another common strategy for the inducible control of protein
activity is to induce physical changes in protein sequence through
the endogenous process of protein cleavage or splicing. As
with methods for inducible protein complex formation, protein
cleavage/splicing can be engineered to allow induction via a
number of different mechanisms including both small-molecule-
based and light-based approaches (Figure 3, Table 2). However,
the mechanisms used to induce protein cleavage/splicing are often
interchangeable, allowing these methods to be adapted to a wider
range of systems and biological questions.
Intein-mediated protein splicing
One method that allows inducible control of protein activity uses
the endogenous post-translational mechanism known as intein-
mediated protein splicing (Table 2). With this method, intervening
polypeptides known as inteins are used to catalyse their own
removal from the flanking polypeptides, or exteins, which are
subsequently joined back together. Inteins are typically removed
in a four-step process involving conversion of the peptide bond
linking the N-terminal extein to an ester or thioester bond and
transfer of the N-extein to the C-extein by transesterification. The
resulting branched ester is then resolved by asparagine cyclization
followed by conversion of the newly formed ester bond linking
the two exteins into an amide bond and hydrolysis of the C-
terminal aminosuccinimide of the excised intein [56,57]. Inteins
are used in biotechnology for a number of different applications,
including the control of protein expression or modification,
post-translational processing and also protein labelling [57], but
perhaps the most valuable application in terms of studying protein
function is to facilitate the control of protein activity. Since inteins
are extensively reviewed elsewhere [57–59], so we will not discuss
their use further here, except to say that they have been engineered
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Figure 3 Illustration of methods for conditional protein splicing or protein cleavage to (in)activate target proteins
(A) Illustration of conditional protein cis-splicing induced by activation of an intein through a change in redox state or via a trigger, which may be addition of a small molecule, as depicted here, a
change in pH, temperature or irradiation with a specific wavelength of light. Protein trans-splicing is also possible, whereby dimerization domains can be used to reassociate split intein fragments
upon addition of a trigger. (B) Illustration of TEV protease-mediated cleavage of a TEV recognition site engineered within a protein of interest leading to protein inactivation upon induction of TEV
protease expression. (C) Schematic representation of CALI/FALI induced by addition of a dye-conjugated ligand or antibody, or via genetically encoded methods involving photosensitizers such as
KillerRed, eGFP, miniSOG or SuperNova. Upon irradiation with a specific wavelength of light these produce ROS (1O2) leading to inactivation of proteins in the immediate vicinity.
Table 2 Summary of methods for conditional control of protein splicing/cleavage
Can be induced by
Technique Protein disruption Timescale Small molecule/hormone Light Temperature pH
Intein-mediated protein splicing Inactivation via protein splicing h
√ √ √ √
Tobacco etch virus (TEV) protease cleavage Inactivation via protein cleavage min Promoter-dependent
Chromophore-assisted light inactivation (CALI) Inactivation by ROS Often <1 s 
√
e.g. Malachite Green:
616–624 nm
KillerRed: 540–580 nm
 
Fluorophore-assisted light inactivation (FALI) Inactivation by ROS <10 min 
√
e.g. FITC 493–518 nm  
to allow conditional protein splicing (CPS), such that the splicing
process is induced by the activation of an intein through reduction
or the addition of a trigger such as light, temperature, pH or the
addition of a small molecule (Figure 3A) [57,60]. These systems
have been used successfully both in cultured cells and in living
animals to interrogate protein function, although they have not
been widely adopted for this purpose perhaps because of their
intrinsic lack of reversibility.
TEV cleavage
One common method for inducible protein cleavage as a
mechanism to control protein activity exploits the ability of
the tobacco etch virus (TEV) protease to cleave a highly
specific seven-amino-acid recognition sequence (E-X-X-Y-X-Q-
G/S) with high efficiency (Figure 3B, Table 2) [61–63]. TEV
is commonly used as a mechanism for the cleavage of fusion
proteins to remove protein affinity tags prior to further protein
analysis [64]; however, this system has also been applied to the
control of protein activity both in vivo and in vitro. Through
genetic modification, the TEV recognition sequence can be
engineered into a protein of interest to allow inducible protein
cleavage and inactivation when in the presence of TEV. TEV
techniques have previously been demonstrated in budding yeast
to provide evidence of a role for separin in anaphase initiation
[65] and has since been applied to the study of proteins in both
Drosophila cell culture and live embryos [66,67]. For example,
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to show that TEV was able to effectively and specifically cleave
a protein containing the recognition sequence in live Drosophila
embryos, Harder et al. [66] expressed the protein Megatrachea
(Mega), a Drosophila claudin protein localized to membrane
compartments of ectodermal cells, containing an artificial TEV
protease cleavage site (TEVpcs) and YFP (Mega-TEVpcs-YFP).
Upon TEV expression using the Gal4/UAS system, Mega-TEVpcs-
YFP no longer showed the correct YFP localization indicating
that the YFP had been cleaved from the Mega fusion protein.
Harder et al. [66] went on to adapt this system to allow induction
of TEV expression at different stages of embryo development
by putting TEV under the control of the heat-shock protein 70
(hsp70), thus generating a mechanism for the temporal control of
TEV-mediated protein cleavage. Using this temporally controlled
system, they were then able to induce cleavage of a Mega-TEVpcs
construct leading to truncation of the Mega protein and subsequent
degradation of the truncated protein [66]. Clearly, a key factor
in determining the timescale of TEV-mediated cleavage is the
promoter from which TEV is expressed. Changes in temperature
using the heat-shock protein are capable of inducing TEV
expression and protein cleavage in Drosophila pupae ∼3 h after
a 45 min heat shock [67], whereas rapamycin-induced expression
in mammalian cells induces cleavage within 150 min [68]. This
may make the approach unsuitable for the study of some processes
that operate on a short timescale.
One disadvantage of TEV is that it readily cleaves itself at a
specific site to yield a truncated enzyme with greatly reduced
activity [69,70]. There have therefore been a number of iterative
changes made to TEV protease to adapt the protease for more
diverse applications, for example a TEV mutant has recently
been designed specifically to be active in the secretory pathway
[71]; various other TEV mutants offer the same recognition site
cleavage, but an increased stability and reduced auto-cleavage
activity [69]. Although TEV offers highly specific and efficient
cleavage, a priori knowledge about protein composition is
required to choose a position where the TEV recognition site can
tolerably be inserted that will inactivate the target protein while
reducing the possibility that the resulting protein fragments will
retain function or even have novel functions of their own. There
is also an optimum level of TEV protease expression at which
cleavage occurs but background activity is minimalized; this level
is likely to depend on both the variation of TEV protease and the
system in which it is applied so would need to be considered
during experimental design [68].
The timescales and spatiotemporal resolution of both intein-
mediated protein splicing and TEV cleavage are dependent on
the engineered mechanism of induction. Although the ability to
customize these techniques allows them to be applied to a wide
range of systems and cellular processes, the fastest acting methods
of protein cleavage/splicing with the highest spatiotemporal
resolution are again those induced by light.
CALI/FALI
One method for light-inducible protein cleavage applied to
the study of protein function is chromophore-assisted light
inactivation (CALI) (Table 2). Chromophores are photosensitive
groups, often responsible for the colour of organic molecules,
which produce highly reactive free radicals such as reactive
oxygen species (ROS) upon illumination with a specific
wavelength of light. Using the CALI approach, a chromophore-
tagged protein of interest is inactivated through mild illumination
for a period of time sufficient to induce generation of ROS and
induce protein cleavage of proximate proteins, but short enough
to ensure that the ROS act within a defined radius [30–40 Å
(1 Å = 0.1 nm)] to minimize off-target effects (Figure 3C)
[72]. The specificity of CALI approaches is determined by
the short half-life of the free radical species, which ensures
that only proteins within a radius of 1.5–6 nm relative to the
chromophore are affected [72–74]. After free radical generation,
proteins are typically inactivated within 1 s, which, combined
with laser irradiation of micrometre accuracies, allows for high
spatial resolution and highly controlled protein inactivation
[74].
Originally, CALI approaches used an antibody-based
mechanism to attach a chromophore, such as the dye Malachite
Green, to a protein of interest (Figure 3C). Fluorophores such
as fluorescin isothiocyanate (FITC), which are more efficient at
ROS production, were later employed in a similar approach called
fluorophore-assisted light inactivation (FALI) [75]. However, the
need for microinjection of a dye-labelled non-function-blocking
antibody specific to the protein of interest limited the widespread
application of these approaches. Subsequent methods made use
of genetic modification to label proteins with a generic tag that
can then be fluorescently labelled through extracellular addition
of a specific reagent (Figure 3C). Proteins tagged with one or
two small tetracysteine (TC) motifs will specifically bind to the
membrane permeable biarsenical dye resorufin-based arsenical
hairpin binder (ReAsH) or the fluorescein-based arsenical hairpin
binder (FlAsH). For example, Marek and Davis [76] used FlAsH
labelling to visualize synaptotagmin I (Syt I) at the neuromuscular
junction (NMJ) in late-stage live Drosophila larvae. Through
photo-inactivation they were able to inactivate Syt I within
seconds and provide supporting evidence for a model, previously
based on genetic data alone, in which Syt I plays a role post-
vesicle docking to mediate vesicle fusion and calcium-dependent
transmitter release [76].
Although dyes are added extracellularly in ReAsH/FlAsH
based CALI/FALI approaches, the application of these techniques
in vivo is limited by the difficult task of achieving sufficient
uptake in live animals and also the inability to spatially control the
production of ROS and limit it to particular cells or subcellular
compartments [77]. There is also the problem of non-specific
binding of the membrane-permeant dyes. For CALI/FALI to
become a more widely used technique, there was therefore a
need for a system that sidestepped the requirement for exogenous
addition and could be encoded completely through genetic
manipulation. There has been some limited success using eGFP,
a tag commonly used to study protein localization and function.
For example, CALI illumination of GFP–myosin II was shown
to result in unequal-size daughter cells during asymmetric cell
divisions in a Caenorhabditis elegans Q neuroblast cell lineage
[78]. It is, however, believed that the chromophore within the GFP
structure is protected by the outer shell meaning the generation of
free radical species upon illumination is restricted and therefore
GFP holds a low phototoxicity [77,79].
KillerRed
The first example of a successful genetically encoded CALI
reagent, with a 1000-fold increase in phototoxicity compared
with GFP, is the GFP-related red fluorescent protein KillerRed,
developed from the non-fluorescent red chromoprotein anm2CP
of Hydrozoa jellyfish (Figure 3C) [79]. Although it was originally
unclear why there was such an improvement in phototoxicity,
a study into the structure–function relationship of KillerRed
by Pletnev et al. [80] provided crystallographic data revealing
unique structural features that may facilitate ROS generation.
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KillerRed has been used in a number of applications in
biological research, such as the control of protein activity
in the study of neuronal development in model organisms
[81], and has been used to induce cell-specific killing of
eukaryotic cells in culture via mitochondrial or membrane-
targeted KillerRed [79]. In this regard, KillerRed has also proved
to have uses in medicine; one recent and exciting application of
KillerRed was to the experimental cancer treatment known as
photodynamic therapy (PDT), which aims to use photosensitizers
to selectively kill tumour cells through ROS generation upon
laser illumination [53,82]. Following subcutaneaous injection of
KillerRed-expressing Escherichia coli (KR-E. coli) into mouse
xenograft models of human carcinoma cell lines the Terekawa
laboratory [82] monitored the intensity and spread of fluorescence
through the tumour cells. After 24 h the KR-E. coli spread
throughout the whole tumour and were subsequently irradiated
with orange light (540–580 nm) to induce ROS production.
The generation of ROS led to necrosis and tumours gradually
disappeared to leave healed skin after just 1 week, demonstrating
the ability of KR-E. coli to kill cancer cells originating from
humans. Although there are many questions still to be answered
before this technique is applicable to humans, these results provide
an insight into the capabilities of genetically encoded CALI
approaches.
KillerRed has proved to be an exciting solution to the
difficulties associated with previous CALI approaches. However,
one limitation is its tendency to homodimerize, which can
potentially interfere with protein function [77,79]. There have
been a number of other novel photosensitizers discovered since,
such as SuperNova, a monomeric form of KillerRed [83], and
the fluorescent flavoprotein mini Singlet Oxygen Generator
(miniSOG), which can also be used to generate an insoluble
deposit of singlet oxygen species that can be stained for
visualization using electron microscopy [84]. More recently, the
toolkit of phototoxic proteins was expanded further with the
addition of KillerOrange, an orange mutant version of KillerRed
that results in ROS formation upon illumination with either blue or
green light, meaning it can be used in combination with KillerRed
or other photosensitizers activated by different wavelengths of
light [85].
CALI/FALI approaches enable specific protein inactivation
through phototoxicity and can act with high spatial resolution
through the ability to express tagged proteins in specific cells
and trigger inactivation at a subcellular level (Table 2). The
expansion of the phototoxic protein toolbox should also allow
for the creation of more intricately controlled systems in which
different proteins can be inactivated at different time points or
in different cell populations, which will form a useful tool both
for fundamental research and for potential medical applications.
However, CALI/FALI-based methods suffer from a number of
limitations, including the requirement for either exogenous ligand
addition or the inclusion of a fairly large protein tag that
may interfere with protein function. Importantly, there is also
potential for off-target effects on proteins in close vicinity to the
ROS generator, challenging the specificity of these approaches.
For example, Guo et al. [86] found that the inhibition of
calcium ion currents, mediated by the class C G-protein-coupled
receptor (GPCR) mGluR8a, was greatly attenuated following
FALI inactivation. Although initial results were consistent with
acute inactivation of mGluR8a, Guo et al. [86] also reported
collateral damage to proximal proteins with no overt link to
pathways of GPCR signalling. These factors have limited the
adoption of such methods to study protein function and cannot
be overlooked when using techniques involving phototoxicity for
protein inactivation.
PROTEIN STABILITY/DEGRADATION
Although protein cleavage or splicing can often lead indirectly to
protein instability and degradation, it is likely that this will occur
after some delay depending on the half-life of the protein. It is
also possible for the resulting protein fragments to retain function
or bind other proteins and perform independent functions of their
own, potentially generating a more severe phenotype than simple
protein knockout alone. It therefore follows that a more thorough
and interpretable approach for complete removal of proteins from
cells is to target them directly for degradation by the endogenous
cellular degradation pathways (Figure 4, Table 3). Although the
direct degradation of target proteins means these methods are
technically irreversible and somewhat limited in their application,
in most cases protein levels return to normal following relief of
the degradation stimulus and thus these methods can still provide
a useful tool for studying protein function [9,10,87]. Methods for
inducible protein degradation generally involve the proteasome
pathway for protein degradation, in which ubiquitin is transferred
from the E1 ubiquitin-activating enzyme to the E2 ubiquitin-
conjugating enzyme and subsequently to a lysine residue within
the target protein in a transfer facilitated by the E3 ubiquitin ligase
[88]. This process is repeated to polyubiquitinate the target protein
until it has a sufficient number of ubiquitin molecules for targeted
degradation by the proteasome [88].
N-end degron
A common strategy for the direct induction of protein degradation
utilizes the UBR1 E3 ligase pathway and the N-end rule (Table 3),
which states that the half-life of a protein is determined by both
the accessibility of lysine residues, for ubiquitination, and the
identity of the amino acid at the N-terminus [89,90]. Varshavsky
[90] demonstrated this principle through cleavage of ubiquitin, via
a yeast deubiquitinating protease, from a fusion protein expressed
in yeast, containing the 5′ end of a lacI linker followed by β-
galactosidase (β-gal), resulting in the exposure of a new N-
terminal amino acid. The half-life of β-gal following cleavage
could then be vastly altered by simply changing the exposed amino
acid residue. For example, β-gal with an N-terminal arginine
or phenylalanine residue had a half-life of ∼3 min, whereas
N-terminal methionine or valine resulted in a half-life greater
than 20 h [89]. This method of degradation is conserved from
bacteria to higher eukaryotes, and means proteins tagged with
the unstable lacI degron can be targeted for degradation within
minutes [90]. However, this strategy is not inherently inducible
and therefore requires modification for the conditional control of
protein degradation.
One of the first examples of an inducible N-end degron involved
the use of a temperature-sensitive dihydrofolate reductase variant
(tsDHFR) where an N-terminal destabilizing arginine was only
exposed at non-permissive temperatures [91]. By fusing the
tsDHFR to the N-terminus of a target protein, degradation can
be induced by a switch to the non-permissive temperature of
35 ◦C, exposing the N-terminus at which point the N-end rule
takes effect (Figure 4A). For example, this system has been
used successfully in Drosophila to inducibly polyubiquitinate an
eGFP reporter protein at the neuromuscular synapse following
a 30 min heat shock at 35 ◦C, in order to track the degradation
of polyubiquitinated proteins [92]. By tracking the degradation
of the eGFP, Speese et al. [92] showed that ubiquitinated
presynaptic proteins are not removed from the synaptic terminal
but rather undergo local proteasome-mediated degradation at pre-
synaptic sites. In addition to examples from Drosophila, this
technique has also been used successfully to characterize many
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Table 3 Summary of methods for conditional control of protein degradation
Can be induced by
Technique Protein disruption Timescale Small molecule/hormone Light Temperature pH
N-end degron Unstable N-end amino acid
ubiquitination
min/h, sometimes <30 min
√
e.g. Methotrexate 
√
e.g. 37–42◦C 
TEV protease-mediated induction
of protein instability (TIPI)
Unstable N-end amino acid
ubiquitination
min/h Promoter-dependent
Auxin-induced degradation (AID) F-box-induced ubiquitination <30 min
√
Auxin   
Proteolysis-Targeting Chimaeras
(PROTACs)
Direct targeting to E3 ligase
complexes
min/h
√
PROTAC   
deGradFP F-box induced ubiquitination min/h Promoter-dependent
Figure 4 Illustration of methods for inducible protein degradation divided into those involving the N-end rule or F-box-based pathways
(A) N-end degron method, involving the exposure of an unstable N-terminal amino acid which can be induced by a number of mechanisms including temperature- or small-molecule-based
mechanisms. This unstable end is subsequently targeted for polyubiquitination by an E3 ligase, such as Ubr1P in yeast, and degraded via the proteasome pathway. (B) TIPI which utilizes TEV
protease-mediated cleavage of a seven-amino-acid TEV recognition site to reveal an unstable N-terminal amino acid, subsequently targeted for proteasome-mediated degradation as for the N-end
degron approach. The efficiency of TEV cleavage is increased by the inclusion of a short SF3b155381–424 domain downstream of the TEV recognition site, which binds to a mutant version of the
human spliceosome subunit 14 (p14*) bringing p14*-TEV to the recognition site. (C) Illustration of the mechanism for auxin-induced degradation of target proteins tagged with an AID. Upon
addition of auxin, the AID-tagged protein is recruited to an engineered E3 ubiquitin ligase SCF complex, containing the TIR1 F-box protein from plants, which binds target proteins in the presence
of the plant hormone auxin. Expressing TIR1 in non-plant cells is enough to result in formation of the SCF complex which then binds AID-tagged proteins in an auxin-dependent manner, leading
to polyubiquitination and degradation via the proteasome. (D) Schematic illustration of the deGradFP method for inducible protein degradation. The GFP-tagged target protein is recruited to an
engineered SCF complex containing the F-box protein NSlmb conjugated to an anti-GFP single-chain antibody (vhhGFP4). Target protein is polyubiquitinated via the recruited E2 ubiquitin ligase
and subsequently degraded via the endogenous proteasome machinery.
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essential proteins in budding yeast [93]. However, such techniques
are generally limited to systems that can survive the required
temperature changes and also to proteins that retain function with
the required N-terminal modification. Despite this, the approach
has since been used successfully in chicken DT40 cells, in which
the method was first tested using a tsDHFR degron fused to eGFP.
Upon transfer of the cells to the non-permissive temperature of
42 ◦C, the protein was rapidly depleted to ∼10% of initial levels
within 90 min leading to undetectable levels after 120 min [94].
Moving cells back to the permissive temperature of 35 ◦C resulted
in an efficient recovery to the pre-depletion level within 150 min.
Su et al. [94] then used the approach to deplete RAD51, finding
that RAD51, which plays an important role in homologous DNA
recombination (HDR), does not stop DNA synthesis but causes
cell cycle arrest in G2, suggesting HDR becomes important at
G2. This, along with the many other applications of tsDHFR-
based approaches, show that, although this method is limited in
its potential applications, tsDHFR can still provide a useful tool
in the study of protein function.
In addition to tsDHFR, a small- molecule-controlled version
of dihydrofolate reductase (DHFR) has also been engineered,
for which the drug methotrexate (MTX) regulates stability of
the N-terminus. Although the presence of MTX fails to inhibit
recognition and therefore polyubiquitination of tsDHFR by E3
ligase, the stable high-affinity interaction between MTX and
DHFR impedes protein unfolding and prevents degradation by
the proteasome [95,96]. This system was demonstrated in both
yeast and mammalian cells in culture, although the occupancy
of the proteome by the MTX–DHFR complex is likely to
inhibit degradation of other cellular proteins leading to off-
target effects [97]. Also, DHFR is required for the production
of tetrahydrofolate, which is subsequently required for the
synthesis of purines, thymidylate and several amino acids [98].
The inhibition of DHFR by MTX therefore interferes with the
synthesis of DNA, RNA and even proteins, meaning MTX
is undesirable as a regulatory small molecule for exogenous
addition.
TEV protease-mediated induction of protein instability (TIPI)
An alternative way in which the N-end degron system can be
made inducible, and more widely applicable, is through the use
of TEV in a technique called TEV protease-mediated induction
of protein instability (TIPI) (Table 3). This technique combines
TEV with the N-end rule, whereby TEV cleaves a recognition
sequence engineered into a cryptic N-degron, attached to the N-
terminus of a target protein, to reveal an unstable N-end amino acid
(Figure 4B) [99]. According to the N-end rule, this unstable amino
acid targets the protein for polyubiquitination and degradation
via the UBR1 E3 ligase pathway [89,90]. TEV protease has
previously been shown to allow degeneracy within its recognition
sequence and is particularly flexible to changes at position 7, the
amino acid residue that forms the N-end following TEV cleavage
[63]. TEV protease can therefore cope with the incorporation
of an amino acid that induces degradation following cleavage
via the N-end rule. Taxis et al. [99] first developed the TIPI
approach by designing a construct containing a reporter followed
by a TEV protease recognition site, N-degron and SF3b155381–424
termed Reporter-TDegX-tag, where X represents the amino acid
at position 7 which becomes the new N-terminal amino acid upon
cleavage. The inclusion of a relatively short SF3b155381–424 domain
allowed for more efficient cleavage as its binding to a mutant
version of the human spliceosome subunit 14 (p14*) recruited
p14*-TEV to the recognition site (Figure 4B). Taxis et al. [99]
initially demonstrated this system in yeast using a GFP-TDegX-
Don1p fusion protein, with p14*-TEV expression driven by the
Gal1 promoter, monitoring cleavage via the release of GFP and
testing the effect of the amino acid at position X on TEV cleavage
efficiency and protein half-life. Phenylalanine or asparagine was
found to provide optimal conditions for both TEV cleavage and
rapid degradation of the target protein Don1p. The effectiveness
of TIPI was shown by using the approach to deplete several
different proteins in yeast, obtaining phenotypes correlating to
those observed via genetic knockdowns [99].
The potential of TIPI as an approach for conditional degradation
is yet to be realized; however, its power and versatility has
recently been demonstrated in some alternative applications. For
instance, TIPI has been further modified (mTIPI) to facilitate
production of recombinant proteins; it does this by blocking
endocytosis in yeast and combating a common problem whereby
highly active endocytosis in protein expression systems reduces
the overall protein yield [100]. For conditional control this method
simply requires expression of the p14*-TEV fusion protein,
which could be induced via the same methods as for TEV
cleavage, including temperature, pH, small molecule addition or
the Gal4/UAS system, making it a versatile tool for inducible
degradation and the study of protein function both in vivo and
in vitro.
Auxin-induced degron
Another way in which proteins can be directly targeted for
degradation by the ubiquitin–proteasome machinery is via F-
box proteins, which bind target proteins and recruit the Cullin–
RING complex, also called the SCF complex consisting of
Skp1, Cullin and F-box, to ubiquitinate the target protein [101].
Eukaryotes contain multiple forms of SCF, whereby the F-box
protein conveys specificity towards different target proteins. One
F-box particularly suited to small-molecule-induced control of
protein degradation is the transport inhibitor response 1 (TIR1)
protein, which binds target proteins in the presence of the plant
hormone auxin and has a highly conserved interaction with the
E3 ligase protein Skp1 (Figure 4C) [102,103]. This is commonly
referred to as an auxin-inducible degron (AID) system (Table 3),
and was initially shown to be applicable to most eukaryotes
(excluding plants), including budding yeast and cell lines derived
from human, mouse, hamster, monkey and chicken [104]. The
AID degron consists of IAA17, also known as AXR3, from
Arabidopsis thaliana and when expressed at either the C- or N-
terminus of GFP in budding yeast also expressing AtTIR1, under
the control of the galactose-inducible GAL promoter, the SCF–
TIR1 complex was able to assemble and degrade GFP to less
than 3% of initial levels within 30 min of auxin addition [104].
This approach was successfully used to degrade several essential
nuclear or cytoplasmic proteins in yeast. However, to apply the
system to mammalian cells, it was first necessary to modify TIR1
to convey a higher thermostability and allow use at 37 ◦C. This
was achieved by sourcing TIR1 from the rice plant Oryza sativa
(OsTIR1), which also provided an improvement over AtTIR1 for
use in yeast [104].
This method has since been used successfully to degrade
both nuclear and cytoplasmic proteins in C. elegans [105] and
mammalian cells [106] to help identify the function of several
different target proteins at specific time points of the cell
cycle. Holland et al. [106] tested five differentially localized
proteins, some of which were known to be incorporated into
protein complexes. Four out of the five AID–YFP-tagged proteins
expressed under doxycycline control (Plk4, CENP-A, TFR2 and
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cyclin B1) showed quantitative protein degradation within 80 min
of auxin addition. Degradation of the other protein studied, H2B,
occurred more slowly, within 3 h [106]. These results show that
AID is capable of rapidly depleting proteins involved in stable
complexes with relatively long half-lives; however, the time taken
for depletion following induction can vary. Holland et al. [106]
demonstrated the ability of AID to induce proteolysis with the
same or very similar degradation kinetics at all phases of the cell
cycle and also found that proteins reappeared almost immediately
upon removal of auxin stimulus. To demonstrate the ability of
AID to study protein function, Holland et al. [106] achieved
rapid functional inactivation of BubR1, an essential component of
the mitotic checkpoint, by depleting endogenous BubR1 protein
with siRNA, replacing it with siRNA-resistant GFP-AID-BubR1
and inducing mitotic arrest through nocodazole addition. GFP-
AID-BubR1 rescued the function of the depleted endogenous
BubR1 and this rescue could be rapidly reverted through auxin-
induced degradation of the GFP-AID-BubR1 fusion protein to
produce a more complete null phenotype than mRNA depletion
alone [106].
The AID approach has since been developed further to increase
versatility through minimization of the degron size and the
inclusion of a series of epitope tags to allow detection using
fluorescence microscopy or commercially-available antibodies
[107]. Morawska and Ulrich [107] developed a series of vectors
for PCR-based genomic tagging strategies containing different
iterations of the AID degron with epitope tag, allowing for both C-
or N-terminal tagging and providing a range of selection markers
which they then demonstrated through application to a series
of different yeast proteins. Although these vectors increase the
versatility and facilitate the use of the AID approach, individual
proteins must still be considered on a case by case basis to design
the most effective degron; it may even be necessary to test multiple
iterations to ensure proteins retain function.
PROTACs
Another chemical-based method for the specific degradation
of target proteins by the endogenous ubiquitin–proteasome
machinery is through the use of heterobifunctional small mo-
lecules known as Proteolysis-Targeting Chimaeras (PROTACs)
(Table 3). PROTACs consist of one moiety that binds the target
protein linked to an E3 ligase to directly recruit the protein for
proteasome-mediated degradation. Initially developed to target
disease-causing proteins for destruction, the first generation of
PROTACs were based on large peptide motifs derived from known
ubiquitin ligase substrates [108]. However, these were limited by
high molecular mass, poor cellular uptake and potential metabolic
instability [109,110]. Following a switch to small-molecule-based
PROTACs, the last decade has seen a series of improvements to
PROTAC technology, aided by the development of small ligands
for a number of E3 ligases, including MDM2 (murine double
minute 2), cIAP1 (cellular inhibitor of apoptosis protein 1), CRBN
(cereblon) and VHL (von Hippel–Lindau protein) (as reviewed in
[110]). Although these improved small- molecule PROTACs were
able to successfully degrade target proteins, the overall uptake of
this technique for the conditional control of protein degradation
has been limited by a number of uncertainties, including PROTAC
stability and E3 ligase binding affinity [109,110]. However, more
recent advances in the field have provided a new generation of
highly specific high-affinity low-molecular-mass PROTACs with
the potential to expand the use of PROTAC technology [111–114].
For example, Bondeson et al. [111] used structure-guided
approaches to develop low-molecular-mass (∼450 Da) high-
affinity ligands for the Cullin-RING ligase 2 VHL E3 complex
(CRL2VHL). Linked to small molecules that bind specific
cellular targets, Bondeson et al. [111] were able to efficiently
degrade specific proteins in cultured cell lines, including the
serine/threonine kinase RIPK2, which is involved in innate
immune signalling, and the oestrogen-related receptor α (ERRα),
which is implicated in the regulation of various cellular
metabolism pathways, with dose-dependent degradation and
maximal degradation levels of >95 and 86% respectively.
Bondeson et al. [111] also demonstrated this approach in vivo
using a PROTAC targeting ERRα, reducing its levels by
∼50% and significantly reducing mouse heart and kidney
tumours by >40%. Using a similar approach, Zengerle et al.
[114] successfully designed potent PROTACs using optimized
drug-like VHL ligands [115] and bromo- and extra-terminal
(BET) bromodomain protein ligands to selectively degrade
certain members of the BET protein family, including the
epigenetic regulator BRD4 previously identified as a potential
therapeutic target for acute myeloid leukaemia and ovarian cancer
[114].
In addition to targeting proteins to the CRL2VHL E3 complex,
potent PROTACs have also been developed to utilize the
interaction between immunomodulatory drugs (IMiDs), such as
thalidomide, and the CRL4CRBN E3 ligase. CRL4CRBN, together
with an IMiD, forms a tertiary complex with the transcription
factor Ikaros, resulting in its ubiquitination and degradation.
This approach has since been used for the efficient and specific
degradation of BRD2, BRD3 and BRD4 by attaching BET
bromodomain protein ligands to an IMiD [112,113].
Although the principle behind PROTAC technology is not
novel, there has been a recent surge of developments to generate
a newer generation of more potent PROTACs, which address
the limitations of previous iterations. These newer PROTACs
offer greatly increased potency while retaining high specificity
to their target proteins both in vitro and in vivo. It is also
possible to modify this specificity through manipulation of
the linker between the two PROTAC moieties [111,114]. The
diversity of recently described examples shows how the PROTAC
approach can work on different protein targets in a number of
different systems. However, compared with small molecules used
in other approaches to conditionally control protein dynamics,
PROTACS are larger and more complex molecules and so
may suffer limitations with respect to their pharmacokinetic
properties.
deGradFP
The F-box/SCF complex-based approach has also been utilized in
the degrade GFP (deGradFP) method to specifically degrade GFP-
tagged fusion proteins via an anti-GFP nanobody/F-box chimaera
(Figure 4D, Table 3). A method to allow specific degradation of
proteins tagged with GFP is desirable as GFP-tagged constructs
already exist for many proteins and degradation can be easily
monitored by the loss of fluorescence. The deGradFP method
involves the engineered F-box fusion protein NSlmb-vhhGFP4,
consisting of an F-box domain derived from the Drosophila
protein Slmb and the single-domain anti-GFP antibody fragment
vhhGFP4 which recognizes GFP and its close derivatives
(Figure 4D) [116]. This method was initially demonstrated in
Drosophila, where, with NSlmb-vhhGFP4 expression restricted
to the posterior of early stage embryos by the Gal4/UAS
system, an EYFP-tagged histone H2A variant (His2Av–EYFP)
was rapidly depleted by the deGradFP system [116]. Caussinus
et al. [116] used the engrailed-Gal4 driver to express both
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NSlmb-vhhGFP4 and nuclear mCherry in embryos ubiquitously
expressing His2Av–EYFP. Using mCherry levels as a reporter for
the expression of NSlmb-vhhGFP4, His2Av–EYFP started to be
degraded after ∼30 min following NSlmb-vhhGFP4 expression,
with less than 10% of the maximum EGFP intensity remaining
after ∼3 h [116]. Caussinus et al. [116] then went on to show
the versatility of the deGradFP approach through the successful
depletion of the cytoplasmic protein Spaghetti squash (Sqh),
nuclear protein Apterous (Ap) and the transmembrane protein
Crumbs (Crb) all of which were tagged with GFP, expressed
in a null background and degraded upon induction of NSlmb-
vhhGFP4 expression via the Gal4/UAS system. There were,
however, a couple of cases in which the deGradFP was not
effective against GFP-tagged target proteins. For example, E-
cadherin/Shotgun (Shg) could not be degraded using this method,
possibly as it exists in a large protein complex which may mean the
GFP tag is not accessible to the vhhGFP4 antibody [116]. Also,
NSlmb-vhhGFP4 was unable to induce degradation of GFP alone,
perhaps as the small size of GFP prevents exposure to the SCF-
recruited E2 enzyme and thus prevents poly-ubiquitination. It
was, however, possible to degrade GFP containing a small nuclear
localization signal via this method, so although it is possible that
a minimum size limit exists, below which degradation does not
occur, this limit must be very close to the size of GFP alone and
should not greatly limit the versatility of the approach [116].
deGradFP has been proven to be a useful approach for the
induced degradation of target proteins particularly in combination
with RNAi knockdowns in order to generate a more effective
depletion of protein levels [117,118]. More recently, a similar
approach involving the modification of the E3 ubiquitin ligase
adapter protein SPOP to alter target protein specificity was
proposed [119]. By fusing an anti-GFP nanobody directly to a
truncated SPOP adapter protein completely lacking its substrate-
binding domain, Shin et al. [119] claim to have developed an
approach that is more efficient than deGradFP, which simply
involves an NSlmb deletion mutant for which the binding domain
has been modified. This remains to be proved in terms of
biological applications, but may offer an alternative in cases where
deGradFP is not effective. deGradFP, and related methods, can
in theory be adapted to allow knockdown of many endogenous
proteins, providing high-affinity antibodies are available for target
proteins [87].
Ubiquitin-independent
Ubiquitin-mediated protein degradation is by far the most
common strategy for control of protein degradation; however,
it has previously been shown that localization to the proteasome
is sufficient for degradation [120] and so it is worth mentioning
here that there are also a handful of methods for the conditional
control of ubiquitin-independent protein degradation. The most
common of these is the C-degron; consisting of a 36 amino
acid sequence from ornithine decarboxylase (ODC), this forms
a bridged association with the proteasome, acting as both the
recognition and degradation initiation signal [87]. An exciting use
of this technique allows for light-induced protein degradation via
the use of LOV2 domains [121]. Renicke et al. [121] designed a
system in which the C-degron, fused to the C-terminus of the LOV
domain, can be masked by the Jα helix under dark conditions, but
exposed upon illumination with blue light via Jα helix unfolding,
leading to ubiquitin-independent protein degradation. Although
this provides an exciting alternative, ubiquitin-dependent methods
remain the most widely used and well-studied methods for
inducible protein degradation.
CONCLUDING COMMENTS AND FUTURE PERSPECTIVES
Manipulation of genes, at the level of DNA or RNA, has proven to
be a specific and immensely powerful way of understanding the
roles of encoded proteins in their native cellular environment.
However, distinguishing between the initial and steady-state
consequences of gene disruption, especially in vivo, is often
problematic. The new generation of tools and methods that are
emerging to meet this challenge address the issue by offering
both rapid and specific control of protein function. Different
sets of tools can be employed across a range of timescales
to challenge biological processes operating at the subcellular,
cellular and multicellular level. Methods for conditional control
of protein complex formation (Table 1), in particular, open the
door to in vivo analysis of biochemical processes operating over
short times (s/min), such as intracellular signalling cascades,
which are initiated within seconds of receiving the stimulus.
Furthermore, the ability to reversibly switch activities on and
off enables the systematic perturbation of biochemical pathways,
thereby revealing how information is processed from upstream
stimulus to downstream effectors at each step and providing
insights into rate-limiting components and feedback control [122].
Repetitive perturbation at different times has particular value in
the dissection of biological systems where frequency variation,
including oscillatory behaviours, encodes information [123,124].
Other techniques, including those that conditionally control
protein splicing/cleavage or degradation, typically operate over
minutes/hour timescales (Tables 2 and 3), but have proven utility
in studying the molecular mechanisms of downstream events,
such as changes in cell proliferation, differentiation, migration or
adhesion, which operate over longer times.
It is important to note, as discussed in the sections above,
that current methodologies for conditional perturbation of protein
function are not without their technical limitations and researchers
must weigh up whether the available tools offer the appropriate
flexibility and precision for the desired experiment. One of the
main considerations for researchers wishing to utilize the methods
we have described is to decide which inducer they should use.
Chemically induced methods have been the mainstay of the field
for many years, but the use of chemical inducers is often restricted
because of their promiscuous binding profiles, which can lead
to off-target effects and cytotoxicity. As we have discussed,
higher-affinity ligands might mitigate these effects, because the
compounds can be used at lower concentrations, but typically
suffer from not being reversible. More fundamentally, however,
the inability to target some chemicals to specific subcellular
localizations, combined with their relatively slow uptake in cells,
with effects occurring in minutes to hours, make these methods
unsuitable for the study of certain biological processes and in vivo
models.
Recently, there has been a surge of activity to develop methods
of induction using light. One of the key attractions of this
approach is that perturbations can be both rapid and reversible, in
a spatially resolved manner. Consequently, with light-dependent
systems, should an activated protein diffuse out of the area in
which it received the activating input, it will then switch off,
preventing phenotypic outputs from losing their spatial resolution
[55]. Correspondingly, there has been a great deal of focus on
improving the properties of the light-sensitive domains used in
these approaches, much in the same way that there have been
iterative improvements made to fluorescent proteins for use in
cell imaging. This will make it possible to tailor the perturbation
dynamics. For instance, in the case of light-induced complex
formation, a derivative of the Cry2 domain (Cry2-olig) with
altered off kinetics may make it more suitable for sequestration
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and inhibition of protein activity [125]. A challenge to future
efforts for improvement to such domains will be not just to
identify variants that confer beneficial properties in isolation, but
ones that retain additive effects of multiple genetic changes; this
will require screening procedures that simultaneously optimize
constructs against multiple parameters.
The ultimate goal of the approaches we have described is to
understand the role of molecules in biological phenomena with
quantitative precision. Quantitative in vivo biochemistry, however,
requires measurement not only of the effects of perturbation on
a given process, but also of the magnitude of the perturbation to
the target protein in time and space. Although reliable molecular
readouts might be available for the former, the latter may
be somewhat harder to measure. Fluorescently labelled target
proteins offer an attractive solution for methods relying on
protein degradation, since fluorescence intensity can provide a
measure of protein concentration with spatiotemporal resolution
[126]. However, although quantification of other perturbations,
e.g. protein cleavage or activation, may be straightforward in
cell populations at fixed time points, measurements with single-
cell resolution or in real time will be much more challenging
to achieve. A number of advanced cell imaging approaches
may make this possible, but these techniques are themselves
technically demanding and may not be widely available to
researchers who do not have access to specialized equipment.
For instance, measurements of protein dynamics (e.g. with
fluorescence cross-correlation spectroscopy, or raster image
correlation spectroscopy) and protein proximity (e.g. with FRET
and fluorescence lifetime imaging) can be employed to determine
effects on protein complex formation [127], while specialist
(e.g. FRET-based) reporters can measure, e.g., the activity
of enzymes responsible for post-translational modifications
[128]. Future developments will therefore have to consider
appropriate strategies, not just to perturb protein function, but
to simultaneously measure the extent of that perturbation along
with the biological effect(s).
Concurrently, an ongoing challenge for technology developers
is to make the techniques universally appealing and easy to
employ. Ultimately, whether a technique is proven to be robust
and fit for purpose will depend on uptake and testing by user
communities. From a practical perspective, it may still take
a significant investment of time to tailor an approach to the
experimental system under investigation, despite efforts to make
the available tools universally applicable. Prior knowledge of
protein structure–function relationships may be required, for
example, to guide the production of fusion proteins that retain
normal activity and respond effectively to regulatory stimuli.
These issues have inevitably limited the uptake of many of these
techniques. Methods that utilize tools that are already widely
employed, such as GFP-tagged proteins, are likely to be among
the most popular in the short term because the methodologies can
be rapidly deployed. For instance, deGradFP will no doubt be of
particular interest to the Drosophila and zebrafish communities,
which are creating transgenic libraries in which endogenous genes
have been tagged with GFP [129,130]. Indeed, such collections
may be the starting point for well-designed temporally controlled
screens, to identify novel genes involved in developmentally
regulated biological processes.
As the field continues to mature, an area of future development
is likely to be how multiple techniques might be combined for
improved spatiotemporal control of a single protein, or for the
induction of more than one protein, which has application in
the engineering and study of artificial networks. Importantly,
conditional control of protein function is not exclusive of genetic
manipulation. Ultimately therefore, as gene-editing ‘knockin’
strategies mature [131], it may become routine to incorporate
any number of different conditional domains on a genome-wide
scale to facilitate such studies.
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